A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW

Xiaodong Liu; Yuanyuan Jin; Wenlong Cai; Keith D. Green; Anwesha Goswami; Sylvie Garneau-Tsodikova; Koichi Nonaka; Satoshi Baba; Masanori Funabashi; Zhaoyong Yang; Steven G. Van Lanen

doi:10.1039/c6ob00381h

A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW

Xiaodong Liu
, Yuanyuan Jin
, Wenlong Cai
, Keith D. Green
, Anwesha Goswami
, Sylvie Garneau-Tsodikova
, Koichi Nonaka
, Satoshi Baba
, Masanori Funabashi
, Zhaoyong Yang
, Steven G. Van Lanen

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Using the ATP-independent transacylase CapW required for the biosynthesis of capuramycin-type antibiotics, we developed a biocatalytic approach for the synthesis of 43 analogues via a one-step aminolysis reaction from a methyl ester precursor as an acyl donor and various nonnative amines as acyl acceptors. Further examination of the donor substrate scope for CapW revealed that this enzyme can also catalyze a direct transamidation reaction using the major capuramycin congener as a semisynthetic precursor. Biological activity tests revealed that a few of the new capuramycin analogues have significantly improved antibiotic activity against Mycobacterium smegmatis MC2 155 and Mycobacterium tuberculosis H37Rv. Furthermore, most of the analogues are able to be covalently modified by the phosphotransferase CapP/Cpr17 involved in self resistance, providing critical insight for future studies regarding clinical development of the capuramycin antimycobacterial antibiotics.

Original language	English
Pages (from-to)	3956-3962
Number of pages	7
Journal	Organic and Biomolecular Chemistry
Volume	14
Issue number	16
DOIs	https://doi.org/10.1039/c6ob00381h
State	Published - Apr 28 2016

Bibliographical note

Publisher Copyright:
© The Royal Society of Chemistry 2016.

Funding

This work was supported by National Institute of Health grants AI087849 (S. V. L.) and UL1TR000117 (S. G.-T. and S. V. L.), a National Science Foundation CAREER award MCB 114927 (S. G-T.), and National Natural Science Foundation of China grants 81261120417, 81321004, and 81273414 (Z. Y.).

Funders	Funder number
National Science Foundation Arctic Social Science Program	MCB 114927
National Institutes of Health (NIH)	UL1TR000117
National Institute of Allergy and Infectious Diseases	R01AI087849
National Natural Science Foundation of China (NSFC)	81273414, 81261120417, 81321004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Biochemistry
Physical and Theoretical Chemistry
Organic Chemistry

Access to Document

10.1039/c6ob00381h

Cite this

@article{1171f22985a346138644643e02f84b2d,

title = "A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW",

abstract = "Using the ATP-independent transacylase CapW required for the biosynthesis of capuramycin-type antibiotics, we developed a biocatalytic approach for the synthesis of 43 analogues via a one-step aminolysis reaction from a methyl ester precursor as an acyl donor and various nonnative amines as acyl acceptors. Further examination of the donor substrate scope for CapW revealed that this enzyme can also catalyze a direct transamidation reaction using the major capuramycin congener as a semisynthetic precursor. Biological activity tests revealed that a few of the new capuramycin analogues have significantly improved antibiotic activity against Mycobacterium smegmatis MC2 155 and Mycobacterium tuberculosis H37Rv. Furthermore, most of the analogues are able to be covalently modified by the phosphotransferase CapP/Cpr17 involved in self resistance, providing critical insight for future studies regarding clinical development of the capuramycin antimycobacterial antibiotics.",

author = "Xiaodong Liu and Yuanyuan Jin and Wenlong Cai and Green, \{Keith D.\} and Anwesha Goswami and Sylvie Garneau-Tsodikova and Koichi Nonaka and Satoshi Baba and Masanori Funabashi and Zhaoyong Yang and \{Van Lanen\}, \{Steven G.\}",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2016.",

year = "2016",

month = apr,

day = "28",

doi = "10.1039/c6ob00381h",

language = "English",

volume = "14",

pages = "3956--3962",

number = "16",

}

TY - JOUR

T1 - A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW

AU - Liu, Xiaodong

AU - Jin, Yuanyuan

AU - Cai, Wenlong

AU - Green, Keith D.

AU - Goswami, Anwesha

AU - Garneau-Tsodikova, Sylvie

AU - Nonaka, Koichi

AU - Baba, Satoshi

AU - Funabashi, Masanori

AU - Yang, Zhaoyong

AU - Van Lanen, Steven G.

PY - 2016/4/28

Y1 - 2016/4/28

N2 - Using the ATP-independent transacylase CapW required for the biosynthesis of capuramycin-type antibiotics, we developed a biocatalytic approach for the synthesis of 43 analogues via a one-step aminolysis reaction from a methyl ester precursor as an acyl donor and various nonnative amines as acyl acceptors. Further examination of the donor substrate scope for CapW revealed that this enzyme can also catalyze a direct transamidation reaction using the major capuramycin congener as a semisynthetic precursor. Biological activity tests revealed that a few of the new capuramycin analogues have significantly improved antibiotic activity against Mycobacterium smegmatis MC2 155 and Mycobacterium tuberculosis H37Rv. Furthermore, most of the analogues are able to be covalently modified by the phosphotransferase CapP/Cpr17 involved in self resistance, providing critical insight for future studies regarding clinical development of the capuramycin antimycobacterial antibiotics.

AB - Using the ATP-independent transacylase CapW required for the biosynthesis of capuramycin-type antibiotics, we developed a biocatalytic approach for the synthesis of 43 analogues via a one-step aminolysis reaction from a methyl ester precursor as an acyl donor and various nonnative amines as acyl acceptors. Further examination of the donor substrate scope for CapW revealed that this enzyme can also catalyze a direct transamidation reaction using the major capuramycin congener as a semisynthetic precursor. Biological activity tests revealed that a few of the new capuramycin analogues have significantly improved antibiotic activity against Mycobacterium smegmatis MC2 155 and Mycobacterium tuberculosis H37Rv. Furthermore, most of the analogues are able to be covalently modified by the phosphotransferase CapP/Cpr17 involved in self resistance, providing critical insight for future studies regarding clinical development of the capuramycin antimycobacterial antibiotics.

UR - https://www.scopus.com/pages/publications/84969216961

UR - https://www.scopus.com/pages/publications/84969216961#tab=citedBy

U2 - 10.1039/c6ob00381h

DO - 10.1039/c6ob00381h

M3 - Article

C2 - 27050157

AN - SCOPUS:84969216961

SN - 1477-0520

VL - 14

SP - 3956

EP - 3962

JO - Organic and Biomolecular Chemistry

JF - Organic and Biomolecular Chemistry

IS - 16

ER -

A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW

Abstract

Bibliographical note

Funding

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this